BioCentury
ARTICLE | Clinical News

ALD-301: Phase I/II data

November 24, 2008 8:00 AM UTC

In a double-blind Phase I/II trial, ALD-301 was well-tolerated and produced no serious adverse events. After 12 weeks, 4 of 11 ALD-301 patients no longer had critical limb ischemia. ALD-301 patients a...